4.4 Article

Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Saxagliptin

Related references

Note: Only part of the references are listed.
Review Medicine, Research & Experimental

Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus

Abd A. Tahrani et al.

ADVANCES IN THERAPY (2009)

Article Endocrinology & Metabolism

Saxagliptin Added to a Thiazolidinedione Improves Glycemic Control in Patients with Type 2 Diabetes and Inadequate Control on Thiazolidinedione Alone

Priscilla Hollander et al.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)

Article Endocrinology & Metabolism

Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes

J. Rosenstock et al.

DIABETES OBESITY & METABOLISM (2008)

Article Gastroenterology & Hepatology

Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma

HB El-Serag et al.

GASTROENTEROLOGY (2004)

Review Medicine, General & Internal

Oral antihyperglycemic therapy for type 2 diabetes - Scientific review

SE Inzucchi

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)

Article Gastroenterology & Hepatology

Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: A case-control study

A Poonawala et al.

HEPATOLOGY (2000)